Tom Curran: Contract between NantHealth and U of Utah “seems a bit expensive”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Starting in 2008, I worked closely with Peter Phillips to establish the Children’s Brain Tumor Tissue Consortium designed to generate a biorepository of rare biospecimens, with associated clinical information and genomic data, that could be shared with the research community.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Tom Curran
Chief scientific officer, executive director, Children's Mercy Children's Research Institute in Kansas City

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Tom Curran
Chief scientific officer, executive director, Children's Mercy Children's Research Institute in Kansas City

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login